Class I Without Evidence? Think Again.

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This scenario repeats more often than it should. There is a widespread assumption that Class I devices somehow escape the clinical evaluation requirement. The logic seems intuitive: lower risk, lower burden. But the MDR does not operate on assumptions. It operates on explicit obligations.

Let me walk you through what the regulation actually requires, what Notified Bodies expect, and where manufacturers consistently misinterpret the rules.

The Core Obligation: Article 61 Applies to All Devices

Article 61 of the MDR is unambiguous. Every medical device placed on the market must be supported by sufficient clinical evidence. The article does not exclude Class I devices. It does not say clinical evidence is only required for Class IIa and above. It says all devices.

This is where the first misunderstanding happens. Manufacturers read “sufficient clinical evidence” and assume that for a low-risk device, sufficiency means less evidence or no evidence. That is not what the text says. Sufficiency is determined by the intended purpose, the risk, and the claims. Not by the classification alone.

If your device is Class I non-sterile, non-measuring, you do not need a Notified Body for conformity assessment. You self-declare. But self-declaration does not mean you bypass clinical evaluation. You still prepare a clinical evaluation report. You still collect and appraise data. The regulatory pathway changes. The obligation does not.

What Does “Sufficient” Mean for Class I Devices?

This is the question that drives confusion. If clinical evidence is required, how much is enough for a simple device? The answer is not found in a fixed number of studies or pages. It is found in the demonstration logic.

You must demonstrate that your device performs as intended and does so without unacceptable risk. For a Class I device with established design, well-known materials, and straightforward function, that demonstration may rely heavily on existing literature, performance testing, and post-market data from equivalent devices.

But you still need to show the pathway. You need to explain why the available data is applicable to your device. You need to identify risks and show how the design mitigates them. You need to appraise the data, not just list it.

Even if your device is a tongue depressor, you need a clinical evaluation report. The report may be short. It may rely entirely on literature and material safety data. But it must exist, and it must follow the structure outlined in MDCG 2020-5.

The Three Pillars of Clinical Evidence for Low-Risk Devices

When I review clinical evaluation reports for Class I devices, I look for three things: clarity on intended use, appraisal of available data, and justification of sufficiency. Let me break these down.

Pillar 1: Clear Intended Use and Claims

Your clinical evaluation starts with defining what the device does and what it claims. This is not a regulatory formality. It defines the scope of evidence you need.

If your device is a surgical retractor, your intended use might be: “To provide temporary exposure of the surgical site during procedures.” Your claim is about function, not outcome. You are not claiming faster healing or reduced infection. You are claiming mechanical function.

This clarity allows you to focus your evidence search. You look for data on materials, mechanical performance, and safety during temporary contact. You do not need clinical outcome studies if you are not making outcome claims.

Pillar 2: Data Appraisal and Applicability

You search the literature. You find studies on similar devices, materials, and applications. But listing references is not appraisal. Appraisal means you evaluate the quality of the data, the relevance to your device, and the applicability to your claims.

A common mistake: manufacturers cite a clinical study on a different device with different materials and say, “This demonstrates safety.” No. It does not. You must explain why the data is applicable. What are the similarities? What are the differences? Do the differences matter?

This is where Notified Bodies and competent authorities focus. They want to see reasoning. They want to see that you understand your device and the evidence base.

Pillar 3: Justification of Sufficiency

After you appraise the data, you must conclude whether it is sufficient. This is not a checkbox. It is a justified statement.

You say: “Based on the literature review, the performance testing, and the established safety profile of the materials, the available data is sufficient to demonstrate that the device performs as intended without unacceptable risk.”

If there are gaps, you acknowledge them. If you need post-market data to close those gaps, you say so and you plan for it in your PMCF. You do not pretend the gaps do not exist.

The Role of Equivalence in Class I Devices

Many Class I manufacturers rely on equivalence to other devices. This is acceptable, but it must be done correctly.

Equivalence under MDR is defined in MDCG 2020-5. You must demonstrate clinical, technical, and biological equivalence. You cannot claim equivalence based on classification alone or general similarity.

I see this error frequently: “Our device is equivalent to other tongue depressors on the market.” This is not a demonstration. You must specify the equivalent device, compare technical characteristics, compare materials, compare intended use, and show that clinical data from the equivalent device is applicable to yours.

If you cannot name a specific equivalent device and justify the equivalence, you cannot use this pathway. You must rely on literature and testing for your own device.

What About PMCF for Class I Devices?

Post-market clinical follow-up is also required for all devices. The scope and methods depend on the risk and the gaps in pre-market data.

For a Class I device with well-established design and extensive literature support, your PMCF may be passive. You monitor complaints, you review vigilance reports, you track any literature updates. You do not necessarily conduct new clinical studies.

But you still document this in a PMCF plan and you update your clinical evaluation report with post-market findings. The obligation exists. The intensity is proportionate.

Why This Matters in Practice

I have seen market surveillance actions triggered by inadequate clinical evaluation reports for Class I devices. Competent authorities sample technical files. If your clinical evaluation is missing or insufficient, you may face corrective actions even if your device has been on the market for years.

The regulatory environment is not static. Audits happen. Spot checks happen. If you assume that Class I means no scrutiny, you are exposed.

From a practical standpoint, preparing a proper clinical evaluation report for a Class I device is not a heavy burden if done correctly from the start. It is a structured document that follows MDCG 2020-5, uses available data intelligently, and justifies conclusions clearly.

The burden comes when you try to retrofit a compliant report after years of assuming it was not needed. Then you face gaps in documentation, missing literature searches, and no PMCF data because no plan was in place.

The Regulatory Logic You Must Understand

The MDR does not exempt devices from obligations based on classification. It scales the intensity of oversight. A Class I device is not reviewed by a Notified Body, but it is still subject to the same foundational requirements: technical documentation, risk management, clinical evaluation, post-market surveillance.

When you write your clinical evaluation report, you are not writing for a Notified Body. You are writing for the market surveillance authority who might review your file in three years. You are writing for the internal audit that needs to verify compliance. You are writing to demonstrate that you understand your device and its evidence base.

Final Reflection

If you are preparing a Class I device for market, start with the assumption that clinical evidence is required. Then determine what type of evidence is sufficient for your specific device. Do not start by looking for exceptions.

The manufacturers who handle this well are the ones who treat clinical evaluation as part of product development, not as a regulatory checkbox. They gather data as they design. They plan their literature search early. They document their reasoning clearly.

The ones who struggle are the ones who wait until submission and then realize they have no documentation, no search strategy, and no understanding of what sufficiency means.

You can avoid this by building your clinical evaluation into your quality system from the start. Even for the simplest devices.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.